Archive

ASH 2015: Trials exploring new settings for monoclonal antibodies in MM

by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.

Nicotinamide reduces risk of skin cancers

by Bruce Sylvester: Treatment with nicotinamide, a form of vitamin B3, significantly lowers the risk of common, non-melanoma skin cancer in high-risk patients, researchers reported on Oct. 21,… read more.

Viagra ups insulin sensitivity in prediabetes

by Bruce Sylvester: Treatment with sildenafil, marketed as Viagra and other trade names, appears to improve insulin sensitivity in persons with prediabetes, as well as lowering a biological… read more.

ASH 2015: Capitalising on recent advances in HL – R/R HL in the brentuximab vedotin era. Professor Ajay Gopal, Seattle Cancer Care Alliance, WA, USA. Dr Robert Chen, City of Hope, Duarte, CA, USA and Professor John Sweetenham, Huntsman Cancer Institute, Saltlake City, USA., discuss where they see the optimal setting for use of brentuximab vedotin following updates at ASH 2015. Click on the video image to view.

ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

ASH 2015: Brentuximab vedotin data shows durable CR five years on – is this cure? Dr Robert Chen, (City of Hope, Duarte, CA, USA) discusses the five year survival data presented at ASH; who of the CR patients to watch and wait and who to go onto allo-SCT; and whether these patients are now cured. Click video image to view.

by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.

ASH 2015: Prognostic score helps assess chances of progression-free survival in HL autologous transplant recipients

by Thomas R. Collins: Researchers have developed a prognostic “score” to gauge the chances of progression-free survival in patients with relapsed or refractory Hodgkin lymphoma who have had… read more.

ASH 2015: Highlights of the 57th American Hematological Society Meeting. Professor Ajay Gopal (Seattle Cancer Care Alliance), Professor Stephen Ansell (Mayo Clinic), Professor John Sweetenham (Huntsman Cancer Institute) and Professor Joseph Connors (Vancouver) share their highlights of a very busy ASH and New Year’s resolutions for their management of lymphoma in 2016. Click video image to view.

AHA 2015: Exercise in short bursts better for Type 2 diabetes

by Bruce Sylvester: When compared to 30 minutes of low-intensity exercise, short-bursts of high-intensity exercise significantly improve cardiometabolic and fitness measures in persons with newly diagnosed Type 2… read more.

UEGW 2015: Vaccination in IBD. An interview with Dr Herbert Tilg, Innsbruck Medical University, Austria. Conducted by Sanjay Tanday

UEGW 2015: Low risk Barrett’s oesophagus: To leave or treat? An interview with Professor Prateek Sharma, University of Kansas Medical Center, USA. Conducted by Sanjay Tanday.

UEGW 2015: Management of IBD after anti-TNF failure. Professor Laurent Peyrin-Biroulet (Nancy, France) discusses his presentation on when to use anti-integrins or anti-TNFs and the iCARE programme sponsored by ECCO.

by Maria Dalby: Managing patients with active disease who fail to respond to anti-TNF therapy remains a key unmet need in IBD. Introducing a free paper session on… read more.